# US 2025/0188124 A1 · Peptide compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0188124 A1
- Document ID: US20250188124A1
- Status: Published application
- Kind: A1
- Application number: 18/782,986
- Filed: 2024-07-24
- Published: 2025-06-12
- Earliest claimed: 2013-03-15
- Assignees: Rhythm Pharmaceuticals, Inc.
- Applicants: Rhythm Pharmaceuticals, Inc.
- Inventors: Shubh Sharma; Leonardus H.T. Van Der Ploeg; Bart Henderson
- Web page: https://patentgrep.com/patent/US20250188124A1

## CPC

- C07K 7/54: with at least one abnormal peptide link in the ring
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/10: for impotence
- A61P 15/12: for climacteric disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/685: Alpha-melanotropin
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to polypeptide compounds that are modulators (e.g., agonists and antagonists) of the melanocortin-4 receptor (MC4R) and pharmaceutical compositions comprising same. The compounds described herein are polypeptide of the following structural Formula (I): or a pharmaceutically acceptable salt thereof. Values and preferred values of the variables in structural Formula (I) are described herein.

## Claims

### Claim 1

An isolated polypeptide of the following structural Formula (I):
or a pharmaceutically acceptable salt thereof,
wherein:
R1 is —H, or a C1-C6 acyl;
R2 is —NR3R4, or —OR5 wherein R3, R4, and R5 are each independently is H or a C1-C6 alkyl;
A1 is an amino acid residue selected from Arg, Lys, Orn, His, Nle, Phe, Val, Leu, Trp, Tyr, Ala, Ser, Thr, Gln, Asn, Asp, Glu, or TzAla; or
A1 is a moiety selected from an optionally substituted C1-C12 alkyl, an optionally substituted C6-C18 aryl, an optionally substituted C5-C18 heteroaryl, an aralkyl wherein the aryl portion is an optionally substituted C6-C18 aryl, and the alkyl portion is an optionally substituted C1-C12 alkyl, or a heteroaralkyl, wherein the heteroaryl portion is an optionally substituted C5-C18 heteroaryl, and the alkyl portion is an optionally substituted C1-C12 alkyl; or
A1 is absent; or
A2 and A8 is each independently an amino acid residue selected from Cys, hCys, Pen, Asp, Glu, Lys, Orn, Dbu, or Dpr, wherein A2 and A8 are pairwise selected so as to be able to form covalent bond between their respective side chains;
A3 is an amino acid residue selected from Ala, Tle, Val, Leu, Ile, Cha, Pro, Ser, Thr, Lys, Arg, His, Phe, Gln, Sar, Gly, Asn, Aib, or
A3 is absent, or
A3 is residue Y, wherein Y is an amino acid selected from amino acids represented by the following structural formulas
wherein:
R11 and R12, each independently, is H, —CH3, phenyl, or benzyl;
R21, R22, R23, and R24, each independently is H, —CH3, —CF3, phenyl, benzyl, F, Cl, Br, I, —OCH3, or —OH;
R31, R32, R33, R34, R41, R42, and R43, each independently is H, —CH3, —CF3, phenyl, benzyl, F, Cl, Br, I, —OCH3, or —OH;
A4 is absent or is an amino acid residue selected from Atc, Ala, QAla, Aib, Sar, Ser, Thr, Pro, Hyp, Asn, Gln, an optionally substituted His, Trp, Tyr, Lys, Arg, sChp, or residue X, where the X is an amino acid selected from amino acids represented by the following structural formulas:
wherein:
R51 and R52, each independently, is H, —CH3, phenyl, or benzyl;
R61, R62, R63, and R64, each independently is H, —CH3, —CF3, phenyl, benzyl, F, Cl, Br, I, —OCH3, or —OH;
R71, R72, R73, R74, R81, R82, and R83, each independently is H, —CH3, —CF3, phenyl, benzyl, F, Cl, Br, I, —OCH3, or —OH;
A5 is an optionally substituted Phe, an optionally substituted 1-Nal, or an optionally substituted 2-Nal;
A6 is Arg; and
A7 is Trp,
wherein any amino acid residue is either in L- or in D-configuration, provided that:
1) A3 and A4 are not both absent;
2) when A4 is an amino acid, A3 is not Aib or Gly; and
3) when A4 is His and A5 is a D-Phe or 2-Nal, A3 is not a D-amino acid or L-Ala;
4) when A2 and A8 each is selected from Cys, hCys or Pen, then:
(a) when A4 is absent, then A3 is not L-His;
(b) when A3 is absent, then A4 is not L-His; and
(c) when A4 is His, then A3 is not Glu, Leu, or Lys.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The polypeptide of claim 1, wherein A3 is an D-amino acid.

### Claim 4 (depends on 1)

The polypeptide of claim 1, wherein A4 is an L-amino acid.

### Claim 5 (depends on 1)

The polypeptide of claim 1, wherein A4 is absent.

### Claim 6 (depends on 1)

The polypeptide of claim 1, wherein A5 is D-Phe or substituted D-Phe.

### Claim at position 7

7-8. (canceled)

### Claim 9 (depends on 1)

The polypeptide of claim 1, wherein A4 is His, optionally substituted at any substitutable position with a substituent selected from F, Cl, Br, I, —CH3, —OH, —CN, amine, —NO2, or —OCH3.

### Claim at position 9

10-12. (canceled)

### Claim 13 (depends on 1)

The polypeptide of claim 1, wherein A4 is an amino acid residue selected from Atc, Ala, QAla, Aib, Sar, Ser, Thr, Pro, Hyp, Asn, Gln, a substituted His, Trp, Tyr, Lys, Arg, sChp, or residue X.

### Claim 14 (depends on 13)

The polypeptide of claim 13, represented by any one of the following structural formulas:
(SEQ ID NO: 36)
Ac-Arg-cyclo[Cys-D-Ala-His(3-Me)-D-Phe-Arg-Trp-
Cys]-NH2;
(SEQ ID NO: 37)
Ac-Arg-cyclo[Cys-D-Ala-His(1-Me)-D-Phe-Arg-Trp-
Cys]-NH2;
(SEQ ID NO: 9)
Ac-Arg-cyclo[Cys-D-Ala-Trp-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 8)
Ac-Arg-cyclo[Cys-D-Ala-Gln-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 7)
Ac-Arg-cyclo[Cys-D-Ala-Asn-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 38)
Ac-Arg-cyclo[Cys-D-Ala-Arg-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 39)
Ac-Arg-cyclo[Cys-D-Ala-Tyr-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 40)
Ac-Arg-cyclo[Cys-D-Ala-D-Pro-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 2)
Ac-Arg-cyclo[Cys-D-Ala-Pro-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 4)
Ac-Arg-cyclo[Cys-D-Ala-Pro-D-Phe(p-F)-Arg-Trp-Cys]-
NH2;
(SEQ ID NO: 41)
Ac-Arg-cyclo[Cys-D-Ala-Atc-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 42)
Ac-Arg-cyclo[Cys-D-Ala-QAla-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 43)
Ac-Arg-cyclo[Cys-D-Ala-sChp-D-Phe-Arg-Trp-Cys]-NH2;
or
(SEQ ID NO: 44)
Ac-Arg-cyclo[Cys-D-Ala-X-D-Phe-Arg-Trp-Cys]-NH2,
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

The polypeptide of claim 1, represented by any one of the following structural formulas:
(SEQ ID NO: 15)
Ac-Arg-cyclo[hCys-Ala-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 14)
Ac-Arg-cyclo[hCys-D-Ala-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 45)
Ac-Arg-cyclo[hCys-D-Ala-D-Phe-Arg-Trp-Pen]-NH2;
(SEQ ID NO: 26)
Ac-Arg-cyclo[Glu-D-Ala-D-Phe-Arg-Trp-Dpr]-NH2;
(SEQ ID NO: 27)
Ac-Arg-cyclo[Glu-Ala-D-Phe-Arg-Trp-Dpr]-NH2;
(SEQ ID NO: 46)
Ac-Arg-cyclo[hCys-Aib-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 47)
Ac-Arg-cyclo[hCys-Sar-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 48)
Ac-Arg-cyclo[hCys-Val-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 49)
Ac-Arg-cyclo[hCys-D-Val-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 50)
Ac-Arg-cyclo[hCys-Gln-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 51)
Ac-Arg-cyclo[hCys-D-Gln-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 52)
Ac-Arg-cyclo[hCys-Ala-D-Phe-Arg-Trp-Pen]-NH2;
(SEQ ID NO: 53)
Ac-Arg-cyclo[D-Pen-D-Ala-D-Phe-Arg-Trp-hCys]-NH2;
(SEQ ID NO: 17)
Ac-Arg-cyclo[Cys-D-Ala-D-Phe-Arg-Trp-hCys]-NH2;
(SEQ ID NO: 54)
Ac-Arg-cyclo[Pen-D-Ala-D-Phe-Arg-Trp-hCys]-NH2;
(SEQ ID NO: 55)
Ac-Arg-cyclo[D-hCys-D-Ala-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 20)
Ac-Arg-cyclo[hCys-Pro-D-Phe-Arg-Trp-Cys]-NH2;
or
(SEQ ID NO: 56)
Ac-Arg-cyclo[hCys-D-Pro-D-Phe-Arg-Trp-Cys]-NH2,
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1)

The polypeptide of claim 1, wherein:
A3 is an amino acid residue selected from Tle, Val, Leu, Ile, Cha, Pro, Ser, Thr, Lys, Arg, His, Phe, Gln, Sar, Gly, Asn, or Aib; and
A4 is an amino acid residue selected from Atc, Ala, QAla, Aib, Sar, Ser, Thr, Pro, Hyp, Asn, Gln, a substituted His, Trp, Tyr, Lys, Arg, sChp, or residue X.

### Claim 17 (depends on 16)

The polypeptide of claim 16, represented by any one of the following structural formulas:
(SEQ ID NO: 57)
Ac-Arg-cyclo[Cys-Val-Gln-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 11)
Ac-Arg-cyclo[Cys-D-Val-Gln-D-Phe-Arg-Trp-Cys]-NH2;
or
(SEQ ID NO: 58)
Ac-Arg-cyclo[Cys-D-Val-His(1-Me)-D-Phe-Arg-Trp-
Cys]-NH2,
or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1)

The polypeptide of claim 1, represented by any one of the following structural formulas:
(SEQ ID NO: 59)
Ac-TzAla-cyclo[Cys-Ala-Gln-D-Phe-Arg-Trp-Cys]-NH2;
or
(SEQ ID NO: 60)
Ac-Glu-cyclo[Cys-Ala-His-D-Phe-Arg-Trp-Cys]-NH2,
or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1)

The polypeptide of claim 1, represented by any one of the following structural formulas:
(SEQ ID NO: 37)
Ac-Arg-cyclo[Cys-D-Ala-His(1-Me)-D-Phe-Arg-Trp-
Cys]-NH2;
(SEQ ID NO: 8)
Ac-Arg-cyclo[Cys-D-Ala-Gln-D-Phe-Arg-Trp-Cys]-NH2;
or
(SEQ ID NO: 7)
Ac-Arg-cyclo[Cys-D-Ala-Asn-D-Phe-Arg-Trp-Cys]-NH2,
or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 1)

The polypeptide of claim 1, represented by any one of the following structural formulas:
(SEQ ID NO: 64)
Ac-Arg-cyclo[Cys-D-Ala-His(1-Me)-D-2-Nal-Arg-Trp-
Cys]-NH2;
(SEQ ID NO: 65)
Ac-Arg-cyclo[Cys-D-Ala-Gln-D-2-Nal-Arg-Trp-Cys]-
NH2;
or
(SEQ ID NO: 66)
Ac-Arg-cyclo[Cys-D-Ala-Asn-D-2-Nal-Arg-Trp-Cys]-
NH2,
or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1)

The polypeptide of claim 1, represented by any one of the following structural formulas:
(SEQ ID NO: 67)
Ac-Arg-cyclo[Cys-D-Ala-His(1-Me)-D-Phe-Arg-Trp-
Cys]-OH;
(SEQ ID NO: 68)
Ac-Arg-cyclo[Cys-D-Ala-Gln-D-Phe-Arg-Trp-Cys]-OH;
or
(SEQ ID NO: 69)
Ac-Arg-cyclo[Cys-D-Ala-Asn-D-Phe-Arg-Trp-Cys]-OH,
or a pharmaceutically acceptable salt thereof.

### Claim 22

An isolated polypeptide of any one of the following structural formulas, or a pharmaceutically acceptable salt thereof:
(SEQ ID NO: 61)
Ac-Arg-cyclo[Cys-D-Leu-His-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 62)
Ac-Arg-cyclo[Cys-D-Ile-His-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 63)
Ac-Arg-cyclo[Cys-D-Tle-His-D-Phe-Arg-Trp-Cys]-NH2;
or
(SEQ ID NO: 10)
Ac-Arg-cyclo[Cys-D-Val-His-D-Phe-Arg-Trp-Cys]-NH2,
or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 1)

A method of treating a disorder responsive to the modulation of MC4R in a subject in need thereof, the method comprising administering to said subject an effective amount of the polypeptide of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 23)

The method of claim 23, wherein the disorder responsive to modulation of the MC4R is type 1 diabetes, type 2 diabetes, obesity, insulin resistance, metabolic syndrome, male erectile dysfunction, female sexual disorder, non-alcoholic fatty liver disease, or non-alcoholic steatohepatitis.

### Claim 25 (depends on 1)

The polypeptide of claim 1 or a pharmaceutically acceptable salt thereof, wherein the polypeptide is formulated as a pharmaceutical composition together with a pharmaceutically acceptable carrier.

### Claim 26 (depends on 1)

The polypeptide of claim 1, represented by any one of the following structural formulas:
(SEQ ID NO: 1)
Ac-Arg-cyclo[Cys-D-Ala-His-D-Phe(p-F)-Arg-Trp-
Cys]-NH2;
(SEQ ID NO: 2)
Ac-Arg-cyclo[Cys-D-Ala-Pro-D-Phe-Arg-Trp-
Cys]-NH2;
(SEQ ID NO: 3)
Ac-Arg-cyclo[Cys-D-Ala-Pro-D-Phe(p-F)-Arg-Trp-
Cys]-NH2;
(SEQ ID NO: 4)
Ac-Arg-cyclo[Cys-D-Ala-Pro-D-Phe(p-F)-Arg-Trp-
Cys]-NH2;
(SEQ ID NO: 5)
Ac-Arg-cyclo[Cys-D-Ala-Ser-D-Phe(p-F)-Arg-Trp-
Cys]-NH2;
(SEQ ID NO: 6)
Ac-Arg-cyclo[Cys-D-Ala-Thr-D-Phe(p-CN)-Arg-Trp-
Cys]-NH2;
(SEQ ID NO: 7)
Ac-Arg-cyclo[Cys-D-Ala-Asn-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 8)
Ac-Arg-cyclo[Cys-D-Ala-Gln-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 9)
Ac-Arg-cyclo[Cys-D-Ala-Trp-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 10)
Ac-Arg-cyclo[Cys-D-Val-His-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 11)
Ac-Arg-cyclo[Cys-D-Val-Gln-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 12)
Ac-Arg-cyclo[Cys-D-Val-Pro-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 13)
Ac-Arg-cyclo[Cys-D-Ser-Pro-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 14)
Ac-Arg-cyclo[hCys-D-Ala-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 15)
Ac-Arg-cyclo[hCys-Ala-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 16)
Ac-Arg-cyclo[hCys-Ala-D-Phe-Arg-Trp-Cys]-OH;
(SEQ ID NO: 17)
Ac-Arg-cyclo[Cys-D-Ala-D-Phe-Arg-Trp-hCys]-NH2;
(SEQ ID NO: 18)
Ac-Arg-cyclo[Pen-D-Ala-D-Phe-Arg-Trp-hCys]-NH2;
(SEQ ID NO: 19)
Ac-Arg-cyclo[hCys-D-Ala-D-Phe(p-F)-Arg-Trp-Cys]-
NH2;
(SEQ ID NO: 20)
Ac-Arg-cyclo[hCys-Pro-D-Phe-Arg-Trp-Cys]-NH2;
(SEQ ID NO: 21)
Ac-Nle-cyclo[hCys-Pro-D-Phe-Arg-Trp-Cys]-NH2;
